Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™
Rhea-AI Summary
Valion Bio (NASDAQ: VBIO) opened Velocity Bioworks, a wholly-owned biomanufacturing facility in San Antonio on May 6, 2026, enabling end-to-end domestic production of Entolimod.
The site employs ~45 scientists and completed tech transfer with incremental scale-up to support GMP manufacturing, positioning Velocity Bioworks to serve Valion's pipeline, national preparedness, and third-party CDMO work.
Positive
- Wholly-owned facility opened on May 6, 2026
- End-to-end domestic manufacturing capability for Entolimod
- Completed tech transfer with incremental scale-up to support GMP manufacturing
- Employs approximately 45 scientists, engineers, and operators in San Antonio
- Positioned for inclusion in the Strategic National Stockpile and CDMO services
Negative
- None.
News Market Reaction – VBIO
In the May 6 session, VBIO gained 1.98%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.3% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Senator John Cornyn recognizes facility's role in advancing radiation countermeasures for cancer patients and
The ceremony, attended by
"Congratulations to Velocity Bioworks on the grand opening of their new manufacturing facility in
"Today is a deliberate milestone, not an opportunistic one," said Michael K. Handley, Chief Executive Officer of Valion Bio. "When we built Valion Bio as a focused immunotherapeutics company, we made a strategic call: we were not going to outsource our future. The companies that earn the trust of
Entolimod is a Toll-like receptor 5 (TLR5) agonist with broad therapeutic potential. The company is advancing Entolimod with the
"We've built Velocity Bioworks to give biotech companies a true end-to-end partner, from development through manufacturing, so they can move faster without compromising quality," said Ania Szymanska, SVP of Quality and Regulatory Compliance at Velocity Bioworks. "That combination of speed, discipline, and continuity is what sets this team apart. At Velocity Bioworks, we are committed to advancing the next generation of biologics with the quality and urgency patients deserve."
The company chose
Today's ribbon cutting marks the operational beginning of Velocity Bioworks as both an internal manufacturing engine for Valion Bio's pipeline and an emerging contract development and manufacturing organization (CDMO) serving third-party biologics clients.
About Valion Bio, Inc.
Valion Bio, Inc. (Nasdaq: VBIO), formerly Tivic Health Systems, Inc., is a clinical-stage immunotherapeutics company activating innate immunity to protect and extend life. The company's lead asset, Entolimod™, is a TLR5 agonist being developed for acute radiation syndrome under the FDA Animal Rule pathway, for oncology supportive care including neutropenia, and for longevity indications. Entolimod™ has received Fast Track and Orphan Drug designations from the
About Velocity Bioworks
Velocity Bioworks is a wholly owned subsidiary of Valion Bio, Inc. and a contract development and manufacturing organization (CDMO) headquartered in
Forward-Looking Statements
This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Valion Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict.
Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of the company's interactions with and guidance from the FDA and other regulatory authorities; the continued interest of BARDA and other
Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Valion Bio's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, under the heading "Risk Factors", as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and the company undertakes no duty to update such information except as required by applicable law.
Contacts
Investor Relations:
Rich Cockrell
Valion Bio, Inc.
Vbio@cg.capital
View original content to download multimedia:https://www.prnewswire.com/news-releases/valion-bio-celebrates-grand-opening-of-velocity-bioworks-biomanufacturing-facility-in-san-antonio-anchoring-domestic-production-of-entolimod-302764113.html
SOURCE Valion Bio, Inc.